Mechanisms that may allow circulating monocytes to persist as CD4 T cells diminish in HIV-1 infection have not been investigated. We have characterized steady-state gene expression signatures in circulating monocytes from HIV-infected subjects and have identified a stable antiapoptosis gene signature comprised of 38 genes associated with p53, CD40L, TNF, and MAPK signaling networks. The significance of this gene signature is indicated by our demonstration of cadmium chloride-or Fas ligand-induced apoptosis resistance in circulating monocytes in contrast to increasing apoptosis in CD4 T cells from the same infected subjects. As potential mechanisms in vivo, we show that monocyte CCR5 binding by HIV-1 virus or agonist chemokines serves as independent viral and host modulators resulting in increased monocyte apoptosis resistance in vitro. We also show evidence for concordance between circulating monocyte apoptosis-related gene expression in HIV-1 infection in vivo and available datasets following viral infection or envelope exposure in monocyte-derived macrophages in vitro. The identification of in vivo gene expression associated with monocyte resistance to apoptosis is of relevance to AIDS pathogenesis since it would contribute to: 1) maintaining viability of infection targets and long-term reservoirs of HIV-1 infection in the monocyte/macrophage populations, and 2) protecting a cell subset critical to host survival despite sustained high viral replication.
M onocytes/macrophages (M/M)
3 bind HIV-1, are a target of HIV-1 infection, and they support continued virus replication (1, 2) , which can be further enhanced by coinfections and immune activation (3) . CD4 T cells, the other target of HIV-1, and the predominantly uninfected peripheral CD4 T cells (4) are known to decline over the course of HIV-1 disease as a consequence of both HIV-1 and bystander mechanisms of apoptosis induction (5) (6) (7) . In contrast, the predominantly uninfected peripheral monocyte pool (8) does not diminish during steady-state viral replication (9, 10) . HIV-1-infected tissue macrophages are proposed to serve as long-lived HIV-1 reservoirs (3). There is limited information on in vivo apoptosis gene expression and functional outcomes for M/M apoptosis response from HIV-1-infected persons. However, data from in vitro models of HIV-1 infection of monocyte-derived macrophages (MDM) have repeatedly shown a relationship between MDM persistence (11, 12) and antiapoptotic regulation in association with the expression of HIV-1 accessory proteins nef or tat (13) (14) (15) . Indeed, our collective understanding of gene regulatory effects present during chronic HIV-1 infection in infected subjects has been defined largely by in vitro models of infection rather than by direct study of HIV-1-infected subjects (16) .
Circulating monocytes in HIV-1 infection have been described as a distinct cell population in comparison to monocytes from uninfected subjects as reflected by their multiple differences in phenotype and function (17, 18) . This disparity is further highlighted by the presence of productive infection in circulating monocytes from infected persons (infectious proviral DNA has been isolated (19, 20) ) in contrast to monocytes from uninfected subjects that remain largely refractory to HIV-1 infection ex vivo until macrophage differentiation. Furthermore, in vivo and in vitro environments are well accepted to be distinct microenvironments such that modulation in vitro lacks a multitude of additional host (21) or microbial (22) regulatory factors that may contribute to overall in vivo regulation of circulating monocyte gene expression during steady-state viral replication in chronic HIV infection.
Here, we describe the identification of a stable antiapoptosis gene signature in association with multiple regulatory networks in circulating monocytes in HIV-1 infection together with a functional resistance to induced apoptosis. Our data provide an in vivo multigene antiapoptosis signature in monocytes from HIV-infected subjects in association with functional resistance to induced apoptosis in contrast to CD4 T cells from the same HIV-infected subjects showing greater apoptosis. We also show monocyte apoptosis resistance to be independently induced by chemokine or HIV-1 envelope ligation of CCR5, indicating a role for CCR5 tropic HIV-1 or immune activation in actively maintaining monocyte survival during chronic HIV-1 infection.
Materials and Methods

Donors, cell subset isolations, and viruses
Chronically HIV-seropositive viremic patients, with a mean age of 43 years and not on therapy, from the Jonathan Lax Immune Disorder Clinic (Philadelphia Field Initiation Group for HIV Trials) served as our donor population for microarray experiments and apoptosis-induction assays. For inclusion, CD4 T cell counts needed to be Ͼ200 cells/mm 3 (mean of 460 cells/mm 3 ) and viral load Ͼ10,000 copies/ml (mean of 32,000 copies/ml) ( Table I) . HIV donors were selected if asymptomatic with no clinical evidence of active comorbidity (from hematocrit, body temperature). Ageand gender-matched healthy HIV-1-seronegative donors from the Wistar Institute Blood Donor Program were included as control subjects. Institutional Review Board approval from the Wistar Institute and Philadelphia Field Initiation Group for HIV Trials (FIGHT) and informed consent from patients were obtained before blood donation. As with HIV-infected donors, uninfected donors with an abnormal temperature, abnormal hematocrit, or reporting any symptoms were excluded. Blood was processed within 2-3 h from drawing. All reagents used were selected for their low levels of endotoxin contamination. PBMCs were separated by Ficoll-Paque (Amersham Pharmacia Biotech) density gradient separation and monocytes were isolated by adherence enrichment or by negative selection following column purification (Miltenyi Biotec, catalog no. 130-091-155) per the manufacturer's instructions. Adherent monocytes were detached from culture by use of cold media and pipetting (not scraping). Flow cytometry at isolation required a minimum of Ͼ90% of cell expression for CD3 Ϫ CD14 ϩ (BD Biosciences; anti-CD14, catalog no. 555399; anti-CD3, catalog no. 555340) with a mean purity of CD14 ϩ monocyte preparations used in the study of 95% (Ϯ3%). The percentage distribution of total CD14 cells between 24 HIV-1 and 16 control subjects tested was found not to be different. Gene expression samples collected from adherent monocyte fractions were collected within 2 h of cell isolation by lysing samples in TRI reagent (Molecular Research Center) as described below, while all functional assays were performed in isolated monocytes subsequently cultured over 36 h in adherent or nonadherent (Teflon) conditions. For functional apoptosis experiments, 21 additional untreated viremic individuals meeting the same criteria and remaining asymptomatic (CD4 T cell counts Ͼ200 cells/mm 3 (with a mean of 438 cells/mm 3 ) and viral load Ͼ10,000 copies/ml (with a mean of 21,766 copies/ml)) served as donors. HIV-1 BAL and HIV-1 aldrithriol-2-inactivated (AT2) virus SF162 were obtained from the Center for AIDS Research viral cell core. M657 inhibitor (23, 24) was kindly provided by M. Miller (Merck). MIP-1␣, MIP-1␤, and RANTES were obtained commercially (R&D Systems, catalog nos. 270-LD, 271-BME, and 278-RN, respectively).
RNA isolation, amplification, and hybridization
Total cellular RNA was extracted from individual enriched monocytes of 13 viremic HIV-1 and 12 control uninfected donors immediately following cell isolation using TRI reagent (Molecular Research Center). One microgram of total RNA was linearly amplified as previously described (25) .
[␣-
33 P]dCTP-labeled cDNA probes (1.6 g) were hybridized to cDNA arrays (manufactured at the Wistar Institute Microarray Facility) that contained 19,200 human probes representing ϳ14,000 known genes. All amplifications and hybridizations were performed in a single batch to minimize experimental variations. Arrays were subjected to high stringency washes, exposed to PhosphorImager screens (Packard Instruments) for 7-10 days, scanned in a Storm 820 PhosphorImager, and visualized using ImageQuant (Molecular Dynamics) (25) . Using the identical approach, RNA was isolated individually from a subset of 4 viremic HIV-1 and 4 control donors selected from this initial group of 13 HIV-1 and 12 control donors after 7-9 mo (in the absence of change in subject characteristics) and hybridized to the same gene filters. The data from this second longitudinal subset served to determine/confirm gene modulation maintained over time.
Gene expression data
The microarray gene expression data discussed in this publication have been deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession no. GSE14542 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc).
Gene expression analysis and study criteria for stable expression
Image analysis was performed using ImaGene 4.0 (BioDiscovery). The radioactive signal intensity measurements obtained were then converted to the corresponding gene expression measurements referred to as normalized median density (NMD) by performing global normalization. The gene expression data obtained by global normalization were renormalized by performing quantile normalization with subsequent log 2 transformation (QL2). The p values were determined using an unpaired heteroscedastic two-tail Student's t test. Statistically significant genes between HIV-1 and control groups had a p value of Յ0.05 when using either NMD-or QL2-normalized data. The false discovery rate of the initial dataset was determined (26) to be 50% for genes with a p value of Յ0.05. Significant genes ( p Յ 0.05) were further selected by differential expression based on an absolute fold change (AFC) value of Ն2 between HIV-1 and control groups when using either NMD-or QL2-normalized data. Genes having a p value of Յ0.05 and an AFC of Ն2 selected in the original 13 HIV-1 subjects and 12 controls and that also exhibited the same expression trend (i.e., up-/down-regulation) in a second sample from 4 of the HIV-1 subjects and 4 of the controls taken seven months after the first samples were considered stably expressed.
Multidimensional scaling and cluster analysis
Multidimensional scaling was performed in two dimensions using nonmetric multidimensional scaling using a Pearson correlation-based distance metric, standard Guttman-Lingoes starting configuration, with a minimum and maximum number of iterations set respectively to 6 and 50. Clustering was performed using the Pearson correlation-based distance metric and Ward linkage. The expression measurements of each gene were converted to z scores by subtracting the mean value of the gene (computed across all samples being clustered) from its expression measurement and dividing the result by the corresponding SD, thus bringing the measurements of every gene to a common scale.
Quantitative real-time PCR and quantitative PCR normalization
PCR was performed in a 20-l reaction volume in an Opticon IV (MJ Research). cDNA from 0.5 g of amplified messenger RNA was prepared using SuperScript II as previously described (25) . PCR product specificity was assessed by melting curve analysis. The expression levels for each gene relative to that in the reference sample, in our case, the Stratagene a Nos. 1-13 served as donors for microarray experiments; the four individuals resampled after 7 mo are indicated as 1a, 2a, 3a, and 4a. Nos. 14 -20 served as donors for protein assays. Donors were asymptomatic and had a history of viremia with Ͼ10,000 copies of virus/ml of plasma and were not on therapy. Viral load and CD4 T cell count measured on the day of blood drawing are indicated.
b Second sample that was taken 7 mo after the initial samples.
Universal Standard RNA, were derived from the fluorescence intensity measurements determined using LightCycler analysis software version 3.5. The housekeeping gene, ␤-actin (ACTB), was selected as an internal control for the amount of cDNA in each assay based on its constant expression observed in our microarray. The primer sequences are indicated in Table II .
Apoptosis induction and caspase-3 assay
Intracellular caspase-3 staining was performed in human cells using the protocol BD Cytofix/Cytoperm permeabilization kit provided by BD Biosciences (catalog no. 554714). After incubation in the presence or absence of 20 M CdCl 2 (Sigma-Aldrich, catalog no. 202908), an established apoptosis inducer (27) (28) (29) (30) (31) (32) (33) (34) (35) , for 20 h, or with 100 ng/ml FasL (Sigma-Aldrich, catalog no. F0427) for 6 h, a million cells were stained with surface Abs purchased from BD Biosciences (CD14 for monocytes), Lineage cocktail (anti-CD56, catalog no. 555516; anti-CD3, catalog no. 555340; CD19, catalog no. 555413; and CD20, catalog no. 555623), and HLA-DR (catalog no. 340549) for Lin Ϫ DR ϩ myeloid cells and CD4 (catalog no. 555349) and CD3 for CD4 T cells. 7-Aminoactinomycin D (7-AAD; BD Biosciences, catalog no. 559925) was used for dead cell exclusion. Cells were incubated for 30 min at 4°C for cell subset phenotyping. Cells were then fixed/ permeabilized and human cells were stained with intracellular anti-active caspase-3 FITC Ab (BD Biosciences, catalog no. 559341) for 30 min at 4°C and measured for active caspase-3 expression on a FACSCalibur flow cytometer. The Abs were titrated to determine the appropriate saturating concentrations. These concentrations were in the range of 0.5-1 g/million cells for all Abs used. Isotype-matched mAbs were used in each staining experiment to determine gates for positive events in monocyte and lymphocyte subsets in all experiments. A total of 100,000 events were collected and analyzed in both control and HIV-1 samples. Before analysis, all samples were gated by forward and side scatter to exclude dead cells, and 7-AAD was additionally used to exclude dead cells. CD14 ϩ caspase-3 ϩ 7-AAD Ϫ cells (percentage of caspase-3) were used to measure CdCl 2 -induced apoptotic monocyte fractions, while CD14 ϩ caspase-3 Ϫ 7-AAD Ϫ cells were used for analysis of live cell fractions (percentage of live cells). Surface annexin-V staining was performed for CD4 T cells using the apoptosis staining kit (Santa Cruz Biotechnology, catalog no. sc-4252 AK). After incubation in the presence or absence of CdCl 2 (100 M) for 20 h, a million cells were stained with surface Abs (CD4 and CD3 for CD4 T cells; from BD Biosciences) and incubated for 30 min at 4°C for cell subset phenotyping. Cells were washed once with buffer (1ϫ PBS with 1% human serum). Five microliters (1 g) 7-AAD and 1.5 l (0.5 g) annexin-V FITC were then added and incubated for 15 min, following which 300 l of 1ϫ annexin-V binding buffer (10ϫ buffer provided with the kit and 1ϫ made fresh on the day of use) was added and analyzed using an EPICS Elite (Beckman Coulter) flow cytometer. As above, a minimum of 100,000 positive events collected for CD4 ϩ CD3 ϩ CD4 T cells in both control and HIV-1 samples were used for analysis. Analysis of acquired data was performed using FlowJo software (Tree Star). Before analysis, all samples were gated by forward and side scatter to exclude dead cells, and 7-AAD was additionally used to exclude dead cells before gating on CD3
ϩ CD4 ϩ (CD4 T cells) for data collection (100,000 events collected).
Annexin-V ϩ 7-AAD Ϫ/dim cells were used for analysis of apoptotic cell fractions (percentage of annexin-V) and annexin-V Ϫ 7-AAD Ϫ cells were used for analysis of live cell fractions (percentage of live cells). 
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Virus and chemokine binding/inhibition assays and CCR5 surface expression
Adherence-enriched monocytes from uninfected donors were cultured for 36 h in the presence of CCR5-tropic HIV-1 BAL (250 pg/ml) or aldrithriol-2-inactivated CCR5-tropic HIV-1 SF162 (AT2R5) (150 pg/ml) to study apoptosis modulation by HIV-1 binding to CCR5, or in the presence of MIP-1␣ (1 M), MIP-1␤ (1 M), and RANTES (1 M) (R&D Systems) as natural CCR5 ligands (36) , following which they were challenged with CdCl 2 (20 M) for 6 h. Intracellular active caspase-3 expression was measured by flow cytometry in the cultured monocytes using the same protocol that was used to measure caspase-3 in ex vivo cells described above. The CCR5 binding inhibitor M657 (1 nM) (24) 
Statistical analyses
For analysis of significance between unrelated groups, unpaired two-tailed Student's t test were used if samples exhibited a normal distribution, a Wilcoxon two-sample test was used when samples exhibited non-normal distribution, and a two-tailed paired Student's t test was used to compare paired treatment groups. For all tests, a p value of 0.05 or less was considered significant. All tests were performed using JMP (SAS Institute) statistical software.
Microarray datasets for comparative analyses
Microarray datasets (significant gene lists) for in vitro macrophage HIV-1 exposure and infection studies were kindly provided by Drs. A. S. Fauci, M. M. Goodenow and S. M. Wahl (37) (38) (39) and were compared with our in vivo significant gene lists to determine genes modulated in both in vivo and in vitro settings, as determined by identical LocusLink IDs.
Pathway analysis
We used three different approaches to explore the functional relationships among the genes identified: DAVID (Database for Annotation, Visualization, and Integrated Discovery; david.abcc.ncifcrf.gov/), the Ingenuity Pathway Analysis tool (www.ingenuity.com), and Pathway Miner tool version 1.1 (BioRag, Bio Resource for Array Genes, at www.biorag.org). We employed DAVID functional clustering and functional annotation clustering algorithms to obtain biologically enriched functional genes groups with reference to our background list containing 19,200 probes based on Fisher exact probability and kappa statistics to define similarity. The second approach conducted using the Ingenuity Pathway Analysis tool examined functional associations among genes and identified significant gene networks on the basis that they had more of the interconnected genes present than would be expected by chance. Overrepresented apoptosis/death-related genes that were functionally relevant in gene networks were identified. We also estimated significant ( p Յ 0.05) overrepresented pathways using the Pathway Miner tool version1.1 that uses a one-sided Fisher exact test to rank significant pathways based on their p values from each of the three different open source pathway resources: KEGG (Kyoto Encyclopedia of Genes and Genomes, www.genome.ad.jp), BioCarta (www.biocarta. com), and GenMAPP (Gene Map Annotator and Pathway Profiler, www.genmapp.org).
Results
Monocytes in chronically infected HIV-1 subjects are characterized by a stable antiapoptosis gene signature in vivo
We first compared baseline gene expression between monocytes from HIV-1-infected persons in the absence of therapy (Table I lists subjects' characteristics) and control donor monocytes. Significant and differentially expressed genes ( p Յ 0.05 and AFC Ն 2) between HIV-1 and control donor monocytes were identified (supplemental Table I ). 4 Among the number of genes found to be differentially regulated, we focused on apoptosis-related genes that were significantly overrepresented by functional group clustering analysis DAVID and identified 58 genes associated with the modulation of apoptosis. Forty-one of these 58 (70.7%) apoptosis genes were validated by retesting a subset of the same donors Ͼ6 mo later (four control and four HIV-1 donors) and establishing these genes as maintaining the same direction of expression (i.e., up-regulation or down-regulation). Importantly, repeat donors had maintained similar viral load and CD4 counts and remained off antiretroviral therapy. Of these 41 genes, 38 genes have been directly reported to have distinct pro-or antiapoptotic function. Fig.  1a shows individual expression patterns of these 38 in vivo-validated genes in both the original 25 samples and the retested 8 repeat samples. Of interest, the 38 apoptosis-related gene signatures alone could segregate HIV-1 and uninfected groups with 97% accuracy (32 of 33) on the basis of their respective differential expression (Fig. 1b) . The regulation of these 38 genes predicted for a greater resistance to apoptosis in circulating monocytes during HIV-1 infection, as 28 of the 38 genes (73.7%) were stably modulated to suggest increased monocyte survival (proapoptotic genes were down-regulated or antiapoptotic genes were up-regulated). The additional 3 genes accounting for the total gene number of 41 4 The online version of this article contains supplemental material. noted above (EDN1, LTB, and NME) are associated with both a pro-or antiapoptotic role and thus are excluded from a Indicated are the accession numbers, gene symbols, and gene names for 21 genes from the stable apoptosis signature that we identify in in vivo HIV-1 monocytes that have also been previously reported as modulated in in vitro macrophages by HIV-1. The references for previous studies that have reported HIV-1-associated modulation of these genes are additionally provided.
acutely stimulated with R5 HIV-1 gp120. Of the 38 stable apoptosis-related genes in vivo, 34 were available for comparison in these independent microarray-based studies and 1 gene was further independently reported as regulated by HIV-1 infection in vitro (41, 42) . Overall, 21 of the 34 apoptosis-related in vivo genes analyzed were also found to be differentially expressed in monocyte/MDM within in vitro cultures exposed to/infected with HIV-1 (Table IV) . Differentially expressed apoptosis genes that were identified to be similarly regulated both in vitro and in vivo included p53 network-associated ( p21), TNF network-associated (IER3 and CCL2), and ERK/MAPK networkassociated genes, including genes induced by CCR5 signaling (LYN and NRAS) (11, 12, 14, 15, 39) . Taken together, this comparative analysis identified surprisingly strong similarities in acute viral-induced regulation as reported in vitro with longterm steady-state regulation of monocytes in vivo indicating that direct viral exposure (or products from infected cells) may have a strong influence on circulating monocyte gene expression despite the fact that monocytes in circulation remain largely uninfected.
HIV-1 monocytes exhibit resistance to apoptosis induction ex vivo
To investigate if circulating monocytes in chronic HIV-1 infection exhibit differential apoptosis resistance when compared with CD4 T cells, we measured expression of molecules indicative of apoptosis (active caspase-3, annexin V) after gating on CD3
ϩ CD4 ϩ (CD4 T cells) positive events in independent HIV-1 donors (subjects satisfying similar criteria for viremia, CD4 T cell count, and no therapy status as in earlier gene expression cohorts) as compared with uninfected donors after ex vivo stimulation with CdCl 2 or FasL. CdCl 2 stimulation was used due to its well-established apoptosis-inducing potential by activation of multiple apoptosis pathways, including activation of p38MAPK/ERK, p53, Fas, oxidative stress, and mitochondrial membrane potential disruption (27) (28) (29) (30) (31) (32) (33) (34) (35) . Consistent with previous reports of constitutive and induced apoptosis in CD3 ϩ CD4 ϩ T cells from HIV-1 subjects (43), we found significantly higher constitutive ( p Ͻ 0.0001) and CdCl 2 -induced ( p ϭ 0.0194) apoptosis in CD3 ϩ CD4 ϩ T cells from HIV-1 donors as compared with controls, based on annexin V expression (Fig. 2) and by live cell subset percentage ( p Ͻ 0.0001 for constitutive live cells and p ϭ 0.0176 for CdCl 2 -induced live cells, results not shown).
We next examined apoptotic induction in monocytes from HIV-1-infected subjects as compared with uninfected subjects by measuring acute induction of active/cleaved caspase-3 expression. We used the active/cleaved caspase-3 assay in the monocyte experiments, as the annexin V Ab was found to cross-react with monocyte membrane annexin V isoforms. CdCl 2 has been shown to induce caspase-3-dependent apoptosis induction in M/Ms (27) . While no difference in constitutive caspase-3 levels was detected between control and HIV-1 monocytes (Fig. 3, a and b) , we observed a significant resistance to CdCl 2 -induced apoptosis in CD3 Ϫ CD14 ϩ monocytes from HIV-1 subjects based on caspase-3 (Fig. 3g-l) to FasL, a more physiologically relevant apoptosis inducer that is known to be elevated in plasma (serum) of viremic subjects (44 -46) . Furthermore, using a gating approach independent of CD14 but inclusive of all myeloid subsets, we show a similar significant resistance to CdCl 2 -induced apoptosis in Lin
Ϫ , CD20 Ϫ ) HLA-DR ϩ cells (which include both CD14-and CD16-expressing monocyte pools and dendritic cells) from the same HIV-1 donors on the basis of caspase-3 ( p ϭ 0.02) and live cell subsets ( p ϭ 0.044, results not shown) (Fig. 3m-r) . Taken together, these observations show apoptosis resistance of monocytes in the presence of active HIV-1 replication in vivo and provide a functional correlate to the presence of a steady-state predicted antiapoptosis gene regulation in HIV-1 monocytes as described earlier.
HIV-1 interactions with CCR5 confer monocyte apoptosis resistance in vitro
Recent reports in murine models have shown that interactions with macrophage/neuron CCR5 confer apoptosis resistance to these cells by inducing ERK/MAPK and PI3K/AKT survival pathways (47, 48) . Given the central role of CCR5 in mediating R5 tropic HIV-1 binding to monocytes and our observed modulation of genes associated with CCR5 and ERK/MAPK signaling (LYN, CCL4, and CCL4L1) (24, 36 , 49), we tested whether CCR5 engagement of uninfected monocytes via HIV-1 envelope for 36 h before CdCl 2 challenge could confer apoptosis resistance in cultured monocytes. First, we tested exposure to infectious HIV-1 BAL; this led to a significant decrease in CdCl 2 -induced apoptosis ( p ϭ 0.012 for CdCl 2 -induced caspase-3 and p ϭ 0.014 for CdCl 2 -induced live cells) based on caspase-3 expression ( p ϭ 0.022) and live cell percentages ( p ϭ 0.023) (Fig. 4a-e) . We also corroborated these observations by demonstrating a decrease in CdCl 2 -induced DNA fragmentation in cultured CD14 ϩ monocytes pretreated with infectious HIV-1 BAL vs in monocytes not treated with virus, using the TUNEL assay (data not shown).
Next, we tested exposure to noninfectious enriched inactivated viral particles. Using aldrithriol-2-inactivated R5 HIV-1 SF162 particles (AT2R5, which can bind but not infect), we once again observed a significant decrease ( p ϭ 0.02) in CdCl 2 -induced caspase-3 expression (Fig. 4f-j) and a significant increase in live cell percentages ( p ϭ 0.022) in cells exposed to AT2R5 (Fig. 4h) . Importantly, we establish a direct role for HIV-1 interactions with CCR5 in mediating MDM apoptosis resistance based on the reversal of AT2R5-mediated apoptosis resistance in the presence of a CCR5 binding inhibitor, M657 ( p ϭ 0.028) (Fig. 4, i and j) . The effect of the inhibitor is further validated by a significant increase in CCR5 expression in MDMs incubated with M657 as compared with MDMs unexposed to M657 ( p ϭ 0.001, results not shown).
CCR5-binding chemokines confer monocyte apoptosis resistance in vitro
We next tested cultured monocyte apoptosis modulation by exposure to the CCR5-binding chemokines MIP-1␣, MIP-1␤, and RANTES before CdCl 2 challenge. Similar to our observations on viral interactions with CCR5, we observed a significant reduction in CdCl 2 -induced MDM apoptosis ( p ϭ 0.039 for CdCl 2 (Fig. 5) . Notably, monocytes from viremic donors demonstrated significantly lower surface CCR5 expression when compared against monocytes from controls ( p ϭ 0.0034), consistent with a role for ongoing in vivo CCR5 signaling by either virus/chemokine binding (Fig. 6) . To test whether differential levels of CCR5-binding chemokines also corresponded with differences between groups, constitutive soluble CCR5-binding chemokine (RANTES, MIP-1␣, MIP-1␤) levels between HIV-1 viremic asymptomatic and uninfected subjects were measured in plasma (n ϭ 20 for each group). Results showed no clear difference between groups (not shown), leading us to conclude that while chemokines are present, chemokine levels alone do not segregate our study groups.
RANTES (
p ϭ 0.007 for CdCl 2 -induced caspase-3 and p ϭ 0.021 for CdCl 2 -induced live cells)
Discussion
Herein we provide the first evidence for the presence of a steadystate, stable antiapoptosis gene expression signature in circulating monocytes in chronic HIV-1 infection in association with monocyte resistance to apoptosis induction. Similarities between monocyte apoptotic gene modulation in vivo with in vitro gene regulation, the down-regulation of CCR5 expression in circulating HIV-1 monocytes in vivo, and our data showing M/M apoptosis resistance following CCR5 binding support a prominent role for viral envelope-mediated interactions and/or chemokine expression in the maintenance of steady-state gene expression in vivo. Indeed, as Ͻ1% of circulating monocytes are directly infected in vivo (8) and monocytes express CCR5 at levels able to bind and signal but not support infection (50) , our data support a leading role for HIV-1 binding or soluble factors in regulating monocyte gene expression in vivo. Finally, gene pathway analysis, in conjunction with a review of published data on the identified apoptotic gene signature in our study, strongly indicate in vivo regulation of p53, CD40, and TNF networks as steady-state features of monocyte apoptosis modulation during chronic HIV infection. Our observations in infected human subjects now complement studies on HIV-1-infected MDMs in vitro, where HIV-1 accessory proteins (such as nef or tat) or envelope-dependent induction of M-CSF have been shown to also contribute to apoptosis modulation within infected cell cultures (13) (14) (15) 51) . Indeed, our circulating monocyte data strongly suggest that apoptosis modulation of monocytes/macrophages is broader than just within infected cells alone. Noteworthy is the strong impact of chronic HIV infection (virus-and host immune activation-mediated effects) on monocyte gene expression, clearly acting to segregate HIV and control samples on the basis of expression of all genes tested (14,000) in our study as a wider definition of a difference than the differentially expressed genes or apoptosis-related genes emphasized in our report. This reflects the overall higher homogeneity in composite gene expression in HIVinfected vs control subjects' monocytes as a consequence of active HIV replication in vivo (supplemental Fig. 1 , see summary multidimensional scaling plot).
An antiapoptotic gene modulation in monocytes from HIV-1-infected subjects as a result of viral envelope binding stands in direct contrast to reports of apoptotic rate in CD4 T cells where HIV-1 envelope binding to CCR5 (p53, MAPK) and host-initiated immune activation pathways (TNF, FAS) are shown to preferentially lead to CD4 T cell death (6, (52) (53) (54) (55) . Indeed, differential monocyte apoptosis may underlie previously reported observations indicating lower monocyte turnover in the presence of HIV-1 replication in vivo in contrast to a higher CD4 T cell turnover (9) . HIV-1 monocyte resistance to FasL (Fig. 3) in addition to CdCl 2 may also bear on the persistence of the circulating monocyte pool during periods of chronic circulating CD4 T cell loss known to be associated with the presence of viral replication and elevated circulating levels of proapoptotic mediators such as soluble FasL, TNF, and TRAIL (44 -46, 56 -58) . Supporting this interpretation is the recent observation of in vitro HIV-1-infected macrophage resistance to TRAIL-induced apoptosis (51) .
As a mechanism of action, we provide evidence for HIV-1 envelope interaction with CCR5 as being able to trigger resistance to apoptosis in monocyte cultures (Fig. 4) . Furthermore, since the CCR5 agonistic chemokines MIP-1␣, MIP-1␤, and RANTES are known to be produced by activated T cells and are elevated in HIV-1-infected individuals (59 -61), our observation showing chemokine/CCR5 binding mediated apoptosis resistance (Fig. 5) establishes the presence of redundant host mechanisms for monocyte protection in the presence of either viral replication or immune activation. Our observation of significantly lower CCR5 expression in monocytes from HIV-infected subjects when compared with controls is consistent with greater engagement and downregulation of CCR5 in vivo (Fig. 6) .
Our data showing a lack of difference in circulating levels of CCR5-binding chemokines RANTES, MIP-1␣ and MIP-1␤ between HIV-1 and control groups is also consistent with our cohort not being at end-stage disease (i.e., Ͻ100 CD4 with Ͼ100,000 copies/ml viral load), as previous studies have shown decreasing levels of serum ␤-chemokines in HIV-1-infected individuals to correlate with severity of disease progression (59, 60, (62) (63) (64) . It remains to be tested whether unchanged expression levels of serum ␤-chemokines we report reflect the preferential recruitment of asymptomatic subjects at mid-stage disease (in absence of comorbidities). It is also possible that quantification of intracellular chemokine levels in monocytes may be required to detect expression differentials specific to this subset.
We also find support for our interpretation of virus/chemokine CCR5 binding mediating monocyte apoptosis resistance in the overrepresentation of in vivo genes otherwise already associated with outcomes of CCR5 ligation by HIV-1 gp120 or chemokines in vitro such as p38/ERK/MAPK pathway genes (including LYN, NRAS, BRAF, PAI2) (24, 37, 47, 48, 65) . Of interest, LYN, which is known to activate ERK/MAPK following in vitro HIV-1 gp120 or MIP-1␤ interaction with macrophage CCR5 (24) , was noted in our results to be up-regulated in circulating monocytes in vivo. A role for p53 in inhibiting apoptosis in infected MDMs in vitro has been suggested by the reported p53-mediated expression of genes (including p21) that inhibit DNA damage-induced apoptosis and facilitate viral replication (38, 39) . p21, which is known to contribute to inhibiting monocyte apoptosis (66) , and p53 (67, 68) in vitro were noted to be up-regulated in vivo, raising p53 regulation/ expression as a potential mechanism of apoptosis regulation in circulating monocytes during HIV-1 infection. Furthermore, our results showing the in vivo up-regulation of the MT gene family (which is modulated by CD40L signaling and IL-6), known to confer apoptotic resistance to a variety of stress inducers (e.g., reactive oxygen species, heavy metals, including cadmium (32), and DNA damage) and to inhibit p53-mediated apoptosis (69), further support our interpretation of p53 expression and associated modulation of gene expression as one target mechanism of action consistent with our data.
Although we interpret CCR5 engagement to be a dominant mechanism of regulation, note that many genes in the 38 group reported herein have not been associated with CCR5, suggesting that HIV-1 monocytes in vivo are likely subject to more than a single mechanism of regulation. Our results may also be limited by the fact that our array does not include all apoptosis genes characterized to date, and thus we cannot exclude regulation of additional genes associated with apoptosis to the steady-state signature described here. We have addressed this limitation via gene network analysis, which further corroborates the presence of a coordinated multigene/redundant expression profile by identifying overrepresentation of distinct and multiple apoptosis gene pathways in monocytes from HIV-1-infected subjects. Another limitation of our data is that we do not establish whether the circulating virus in each of the subjects studied is CCR5 or CXCR4 tropic other than to expect, based on natural history studies and isolates predominant in midstage disease, that R5 isolates are highly likely to be overrepresented in our cohort. Indeed, CCR5 coreceptors utilizing macrophage tropic HIV-1 are the predominant strains for viral transmission in vivo and predominate until the detection of X4 strains (utilizing CXCR4 as coreceptor), the emergence of which correlates with rapid progression to an AIDS-defining illness or a CD4 T cell count of Ͻ200 cells/l (70 -73) . Future work will need to determine whether CXCR4 signaling (via CXCR4 tropic viruses) can also confer resistance to apoptosis in monocytes/macrophages independently of immune activation. Taken together, we conclude that in chronic HIV-1 infection, the convergence of multiple and complementary gene pathways as a result of virus binding (LYN up-regulation via CCR5 signaling), host factors (CD153, CD40L, TNF and IL-6), regulation of monocyte signaling (MAPK), and transcription (NF-B, ETS1, and p53) act in concert to impart apoptosis resistance in monocytes from HIVinfected subjects. Additional studies will be needed to determine the degree of redundancy between individual molecules or pathways in accounting for the functional apoptosis regulation present in monocytes from HIV-1 subjects.
While a driving concern of our approach remains the potential for contamination by nonmonocyte cells in our gene expression studies and functional analyses, multiple reasons make this concern minimal when evaluating our body of evidence that: 1) gene expression data or antiapoptosis responses were confirmed in both adherent monocyte cultures and in nonadherent cultures (isolation for nonadherent cells by negative selection columns) with yields Ͼ98% viable CD14 ϩ monocytes in each method; contributions of minor nonmonocyte populations that differed from sample to sample would not have attained a p value that was considered significant in the microarray studies presented ( p Ͻ 0.05 and fold change Ͼ2); 2) our apoptosis induction data on lymphocytes and gene expression on isolated lymphocytes in the literature do not resemble data on monocytes; lymphocytes in fact undergo apoptosis, an opposite response compared with monocytes, as shown herein; 3) we observed concordance between genes reported here in circulating monocytes and gene expression profiles described for isolated macrophages infected with HIV-1 in vitro or exposed to viral envelope independently; and 4) all flow cytometry data on apoptosis were obtained by CD14 staining, thereby restricting events to monocytes.
That CCR5 agonistic chemokines mediate monocyte apoptosis resistance appears paradoxical in that the host's natural anti-HIV-1 immune response via activated CD8 T cells, CD4 T cells, and macrophages (all of which secrete MIP-1␣, MIP-1␤, and RANTES) at the time of infection or chronic disease (i.e., lymphoid tissue (3, 74) ) may also act to directly benefit HIV-1 by promoting monocyte survival, thereby actively preserving targets for new infection as well as promoting a host-mediated "cellular sanctuary" site for viral reservoirs. The predicted survival of infected M/M and bystander M/M targets for infection in the face of active HIV-1 replication and death of CD4 T cells may thus bear on the selection for CCR5-dependent (R5) virus at acute infection and throughout the disease (75) . It remains to be determined whether the addition of CCR5 inhibitors to current regimens that are unable to fully suppress viral replication even if reaching "undetectable" status (76) could act to further restrict pathogenic mechanisms for viral persistence by preventing access to long-lived infected M/M pools, thereby not only treating viral replication but also persistence mechanisms. Our initial analysis of monocyte apoptosis induction following regular antiretroviral therapy currently under investigation (i.e., in absence of CCR5 inhibitors) indicates a partial retention of monocyte resistance to apoptosis that, if confirmed, may reflect ongoing CCR5 engagement by the host independently of antiretroviral therapy-induced viral suppression.
Importantly, in contrast to CD4 T cells, M/M populations directly contribute to maintenance of the physiology of multiple systems such as immune function (dendritic cells, resident macrophage populations), hemopoiesis (RBC production), bone metabolism, and thymic function, as also reflected by the absence of any viable myeloid knockout mice to date. HIV-1 envelope may have adapted to exploit the effects of CCR5 on macrophage subsets during active replication, thereby prolonging the host's virus transmission window, as monocytes are critical to sustain core physiological host functions during an otherwise active and progressive infection. It will be important to determine whether similar apoptotic gene modulation in M/M populations is present in other chronic human infections where microbial persistence is intricately associated with chronic immune activation and macrophage infection/persistence.
